Substance use during pregnancy and the postnatal period presents complex clinical and social challenges. Midwives often encounter women who use psychoactive substances, ranging from socially accepted substances like alcohol and tobacco to illicit drugs such as opioids, cannabis, and amphetamines. In the Nigerian context, self-medication and the misuse of prescription medications also contribute significantly to prenatal substance exposure. Understanding this landscape requires looking beyond the moral stigma to recognize addiction as a chronic, relapsing brain disorder. When a pregnant woman uses substances, she faces unique physiological and psychological pressures that can intensify dependency. Comprehensive maternity care must approach substance use with empathy, recognizing that punitive measures drive women away from healthcare facilities, increasing risks for both mother and baby.
Chronic substance use alters neurochemical pathways in the brain, particularly the reward system involving dopamine. Repeated exposure changes receptor sensitivity, leading to tolerance and physical dependence. Clinically identifying these disorders during antenatal visits requires keen observation and clinical awareness.
Childbearing women experience distinct biological, psychological, and social vulnerabilities regarding substance use. Hormonal fluctuations during pregnancy and the puerperium can heighten mood instability, sometimes driving self-medication with alcohol, sedatives, or illicit drugs to cope with anxiety or depression. Women frequently metabolize drugs differently due to expanded blood volume, altered renal clearance, and changes in hepatic enzyme activity. Socially, women face heavier stigma than men, often fearing the loss of custody of their children or community ostracization. This intense fear of judgment creates a powerful barrier to disclosing substance use, making confidential and non-judgmental midwifery support vital.
Early and routine screening is the cornerstone of effective intervention. Midwives should integrate non-judgmental screening into the booking visit and repeat it periodically. Standardized, validated questionnaires help remove personal bias from the assessment process.
Tools like the CRAFFT or AUDIT are widely utilized, while the 4Ps Plus tool specifically addresses parental history and substance use. Assessment should never feel like a police interrogation. A conversational approach builds trust, allowing the woman to share accurate history regarding her substance use, frequency, and last time of use. Physical assessments and urine toxicology screens, where legally and ethically appropriate, complement the history-taking process.
Substance use disorders significantly elevate maternal morbidity and mortality. Physiological stress from intoxicants and withdrawal places immense strain on the cardiovascular and respiratory systems. Obstetric complications are frequent and severe.
| Substance Class | Major Obstetric Complication | Systemic Maternal Risk |
|---|---|---|
| Opioids | Preeclampsia, Preterm labor | Sepsis, Overdose |
| Stimulants (Amphetamines/Cocaine) | Placental abruption, Uterine rupture | Hypertensive crisis, Stroke |
| Alcohol | Spontaneous abortion, Abruptions | Malnutrition, Liver disease |
| Tobacco | Placental abruption, Preterm premature rupture of membranes | Respiratory illness, Heart disease |
Midwives must maintain high clinical vigilance, monitoring vital signs closely and recognizing early signs of obstetric emergencies.
Substances cross the placenta readily, exposing the developing fetus to direct toxicity and chronic hypoxia. Intrauterine growth restriction, congenital anomalies, and fetal demise are devastating potential outcomes. Following delivery, the sudden removal of the maternal supply chain plunges the newborn into withdrawal.
Neonatal Abstinence Syndrome (NAS) manifests as hyper-irritability, high-pitched crying, tremors, poor feeding, frantic sucking, tachypnea, and gastrointestinal distress. The Finnegan Scoring System is the standard tool used to assess symptom severity and guide pharmacological or supportive treatment in the neonatal unit. Midwives must work closely with pediatric colleagues to monitor transitional care and support maternal-infant bonding despite withdrawal challenges.
Managing addiction in pregnancy requires balancing maternal stability with fetal safety. Abrupt cessation of certain substances, particularly alcohol and opioids, can cause severe withdrawal that endangers the fetus. Therefore, medically supervised withdrawal or opioid agonist therapy (OAT) using medications like methadone or buprenorphine is often recommended over unassisted withdrawal.
Pharmacotherapy must always be paired with psychosocial interventions. Counseling, cognitive behavioral therapy, and peer support groups address the underlying psychological drivers of addiction. Midwives act as vital links in the multidisciplinary team, coordinating care between obstetricians, mental health specialists, and social workers to support recovery.
The postnatal period is a time of high vulnerability for women with addiction disorders, as sleep deprivation and the demands of newborn care can trigger relapse. Midwifery-led care centers on continuous, compassionate support that preserves maternal dignity. Midwives must actively challenge institutional stigma among healthcare colleagues, fostering an environment of trust.
Postnatal care plans should include mental health check-ins, contraception counseling, and connection to community-based recovery resources. Promoting rooming-in and breastfeeding, when clinically safe, strengthens the mother-infant attachment. By offering non-judgmental, holistic guidance, midwives empower women to maintain long-term recovery and build healthy families.